Trials / Completed
CompletedNCT00124020
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 771 (actual)
- Sponsor
- Cumberland Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study 0019 (NCT00124020) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Telavancin | Telavancin 10 mg/kg/day IV for up to 21 days |
| DRUG | Vancomycin | Vancomycin 1 Gm administered every 12 hrs IV for up to 21 days |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2007-05-01
- Completion
- 2007-05-01
- First posted
- 2005-07-26
- Last updated
- 2019-01-16
- Results posted
- 2010-02-01
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT00124020. Inclusion in this directory is not an endorsement.